Evidence map›Paper›PMID 41210994›Full record

ArticleiScience2025

Development of retinoid nuclear receptor pathway antagonists through targeting aldehyde dehydrogenase 1A3.

Mark Esposito, Cao Fang, Yong Wei, Alfonso Pozzan, Claudia Beato, Xiaoyang Su, Josiah E Hutton, Tavis Reed, Xiang Hang, Enrico D Perini and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mark EspositoDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
Cao FangDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
Yong WeiDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
Alfonso PozzanAptuit (Verona) Srl, an Evotec Company, Verona, Italy.
Claudia BeatoAptuit (Verona) Srl, an Evotec Company, Verona, Italy.
Xiaoyang SuRutgers University Robert Wood Johnson Medical School, New Brunswick, NJ 08904, USA.
Josiah E HuttonDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
Tavis ReedDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
Xiang HangDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
Enrico D PeriniWuXi AppTec, Shanghai, China.
Wen WangWuXi AppTec, Shanghai, China.
Xiaobing ChengWuXi AppTec, Shanghai, China.
Yan PanWuXi AppTec, Shanghai, China.
Jianshi YuDepartment of Pharmaceutical Sciences, University of Maryland, Baltimore, MD 21201, USA.
Maureen KaneDepartment of Pharmaceutical Sciences, University of Maryland, Baltimore, MD 21201, USA.
Malini ManoharanDeepKnomics Labs, Bangalore, India.
John ProudfootDiscoveryBytes LLC, Newtown, CT, USA.
Ileana M CristeaDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.
Yibin KangDepartment of Molecular Biology, Princeton University, Princeton, NJ 08544, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aldehyde dehydrogenase 1a3 (ALDH1A3) activity is recognized as a pathogenic trait in cardiometabolic diseases and cancer, though the mechanisms by which ALDH1A3 promotes disease are unclear and effective therapeutic inhibitors of ALDH1A3 are lacking. Whereas the function of the ALDH1A enzymes in development is the conversion of retinaldehyde into all-

Indexed as

CancerCell biology

Identifiers

PMID41210994
PMCPMC12595434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.